Keyphrases
Acute Myocardial Infarction
29%
Advanced Therapies
25%
Advanced Therapy Medicinal Products
49%
Adverse Drug Reaction
100%
Adverse Reactions
11%
BNT162b2
23%
ChAdOx1
19%
Clinical Development
11%
Clinical Practice
38%
Clinical Trials
46%
Comorbidity
18%
Drug Provocation Test
13%
Drug Treatment
12%
Elderly Patients
14%
Elderly People
32%
Electronic Medical Records
12%
European Countries
17%
European Union
38%
Hip Fracture
13%
Hospital Physicians
13%
Hospital Setting
12%
Immunogenicity
12%
Inappropriate Prescribing
19%
Marketing Authorization
22%
Multicentric
11%
Multiple Sclerosis
11%
Off-label Use
39%
Older Patients
16%
Older People
11%
Pacientes
13%
Patient Register
11%
Pediatric Hematology
19%
Pharmacovigilance
26%
Pharmacovigilance System
14%
Polypharmacy
18%
Potentially Inappropriate Medication
19%
Reactogenicity
22%
Real-world Practice
10%
Regulatory Framework
11%
Rituximab
32%
SARS-CoV-2 Infection
11%
Secondary Prevention
19%
Spain
32%
Spontaneous Reporting
16%
Spontaneous Reports
11%
STOPP Criteria
11%
Systemic Lupus Erythematosus
12%
Tertiary Hospital
18%
United States
29%
β-lactam Antibiotics
13%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
15%
Acute Heart Infarction
31%
Acute Kidney Failure
9%
Adrenergic Receptor Blocking Agent
9%
Adverse Drug Reaction
90%
Adverse Event
43%
Adverse Event
9%
Anticoagulant Agent
30%
Benzodiazepine
9%
Beta Adrenergic Receptor Blocking Agent
10%
Beta Lactam
10%
Beta Lactam Antibiotic
13%
Biological Product
9%
Cardiovascular Risk
19%
Clinical Pharmacology
9%
Clinical Trial
45%
Cohort Study
14%
Diabetes Mellitus
13%
Disease
26%
Diseases
9%
Heart Infarction
9%
Hip Fracture
19%
Hydroxychloroquine
10%
Immunoassay
13%
Immunogenicity
16%
Indicator
9%
Infection
18%
Infection
9%
Interferon
11%
Kidney Disease
10%
Messenger RNA
9%
Multiple Chronic Conditions
13%
Observational Study
14%
Off-Label Use
39%
Orphan Drug
9%
Pharmacoepidemiology
9%
Pharmacotherapy
12%
Pharmacovigilance
40%
Polypharmacy
21%
Prevalence
15%
Prospective Study
13%
Provocation Test
13%
Psychotropic Agent
9%
Receptor
19%
Remission
12%
Retrospective Study
42%
Rituximab
34%
SARS Coronavirus
26%
Systemic Lupus Erythematosus
10%
Vaccine
9%
Medicine and Dentistry
Acute Heart Infarction
9%
Acute Kidney Injury
9%
Advanced Therapy
39%
Adverse Drug Reaction
19%
Adverse Event
22%
Anticoagulation
9%
Antithrombotic
20%
Asthma
9%
Atrial Fibrillation
9%
B Cell
11%
Breathing
9%
Cardiovascular Risk
9%
Clinical Trial
22%
Coronary Angiography
9%
COVID-19 Vaccination
9%
Decision Making
9%
Diseases
13%
Drug Therapy
12%
Elderly Population
9%
Electronic Nose
9%
Health Care Cost
20%
Heart Muscle Revascularization
9%
Hip Fracture
9%
Hospital
9%
Human Immunoglobulin
9%
Hydroxychloroquine
9%
Immunoassay
11%
Immunogenicity
16%
Immunoglobulin
9%
Infection
13%
Malignant Neoplasm
13%
Medicine
11%
Messenger RNA
9%
Myositis
9%
Nephropathy
9%
Neutralization
12%
Observational Study
13%
Off-Label Use
9%
Orphan Drug
12%
Patient
14%
Programmed Death-Ligand 1
9%
Provocation Test
9%
Reactogenicity
22%
Receptor Binding
17%
Reimbursement
19%
Retrospective Study
20%
Rituximab
9%
Severe Acute Respiratory Syndrome Coronavirus 2
24%
Therapeutic Procedure
10%
β-Lactam antibiotic
9%
